Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Mar 3;71(5):1231–1240. doi: 10.1007/s00280-013-2117-x

Fig. 2.

Fig. 2

Tumor volume as a function of time in control and treated mice. a Tumor1 after dosing with everolimus (0.5 mg/kg), sorafenib (10 mg/ kg), and the combination (everolimus 0.5 mg/kg and sorafenib 10 mg/ kg). b Tumor2 after dosing with everolimus (1 mg/kg), sorafenib (20 mg/kg), and combination (everolimus 1 mg/kg and sorafenib 20 mg/kg) (Tumor volume measured up to day 30). c Tumor2 after dosing with everolimus (0.5 mg/kg), sorafenib (10 mg/kg), combo-low (everolimus 0.5 mg/kg and sorafenib 10 mg/kg), and combo-high (everolimus 1 mg/kg and sorafenib 20 mg/kg) (Tumor volume measured up to day 28). *p <0.05, compared to the control; #p <0.05, compared to individual treatments (p = 0.03—Placebo vs. everolimus treatment, p value = 0.05—Placebo vs. sorafenib treatment, p value = 0.05—Placebo vs. combination treatment)